Tilator- What I heard is PAR deal paid a lot upfront, thus profit share is low. The MNK deal was less upfront but higher percentage of profits. The problem I see with the MNK deal is that MNK has not established a significant market presence- poor sales numbers... The problem I see with ANDAs in general is too much competition and thus eroding generics prices.